# Ipamorelin sources and research limits

Checked November 17, 2026.

[1] Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139:552–561. DOI 10.1530/eje.0.1390552. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/

[2] Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16:1412–1416. DOI 10.1023/A:1018955126402. PMID 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/

[3] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. Published online 2014. DOI 10.1007/s00384-014-2030-8. PMID 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/ Trial NCT00672074. https://clinicaltrials.gov/study/NCT00672074

[4] FDA. October 29, 2024 Pharmacy Compounding Advisory Committee briefing, ipamorelin section. https://www.fda.gov/media/182088/download

[5] FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Ipamorelin acetate entries. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

[6] PubChem. Ipamorelin, CID 9831659. https://pubchem.ncbi.nlm.nih.gov/compound/9831659

[7] Ankersen M et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of Medicinal Chemistry. 1998. DOI 10.1021/jm9801962. PMID 9733495. https://pubmed.ncbi.nlm.nih.gov/9733495/

[8] Bowers CY et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism. 1990. PMID 2108187. https://pubmed.ncbi.nlm.nih.gov/2108187/ The agent studied was the reported GHRP, rather than the ipamorelin combinations discussed in contemporary marketing.

[9] HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. October 2026, Appendix A. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Notice https://www.federalregister.gov/d/2026-22192
